APRE insider buying and SEC filings, explained
Aprea Therapeutics, Inc. · CIK 1781983
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Mar 31, 2026 | Other purchase | John P. Hamill (CFO) bought 61,956 Pre-Funded Warrant in 2 share classes at $0.8100 ($25K for the 30,978 shares with a reported price) in a private placement. New position of 30,978 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 1, 2026 |
| Mar 31, 2026 | Other purchase | Richard Peters (Director) bought 247,830 Pre-Funded Warrant in 2 share classes at $0.8100 ($100K for the 123,915 shares with a reported price) in a private placement. New position of 123,915 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 1, 2026 |
| Jan 30, 2026 | Other purchase | Oren Gilad (CEO and Director) bought 56,200 Common Stock in 2 share classes at $0.8900 ($25K for the 28,100 shares with a reported price) in a private placement. Holdings of Common Stock up 8% to 373,720 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 2, 2026 |
| Jan 30, 2026 | Other purchase | John P. Hamill (CFO) bought 11,400 Common Stock in 2 share classes at $0.8900 ($5K for the 5,700 shares with a reported price) in a private placement. Holdings of Common Stock up 21% to 33,433 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 2, 2026 |
| Dec 10, 2025 | Other purchase | Marc Duey (Director) bought 42,918 Common Stock in 2 share classes at $1.17 ($25K for the 21,459 shares with a reported price) in a private placement. Holdings of Common Stock up 9% to 256,155 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 11, 2025 |
| Dec 10, 2025 | Other purchase | John P. Hamill (CFO) bought 10,000 Common Stock in 2 share classes at $1.17 ($6K for the 5,000 shares with a reported price) in a private placement. Holdings of Common Stock up 22% to 27,733 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 11, 2025 |
| Dec 10, 2025 | Other purchase | Oren Gilad (CEO and Director) bought 42,918 Pre-Funded Warrant in 2 share classes at $1.17 ($25K for the 21,459 shares with a reported price) in a private placement. New position of 21,459 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 11, 2025 |
10 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow APRE in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.